Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS)


The benefits of lowering a systolic blood pressure below 140 mmHg in elderly hypertension remain controversial. This study is a prospective, randomized, open-label study with blinded assessment of endpoints to compare the 2-year effect of strict treatment to maintain systolic blood pressure below 140 mmHg with that of mild treatment to maintain systolic blood pressure below 160 but at or above 140 mmHg in elderly hypertensive patients. Patients with essential hypertension (65–85 years old, with a pretreatment systolic blood pressure of above 160 mmHg) were randomly assigned to receive strict treatment (n=2,212) or mild treatment (n=2,206). The baseline drug was efonidipine hydrochloride, a long-acting calcium antagonist. The primary endpoint was the combined incidence of cardiovascular disease and renal failure, and the secondary endpoints were total deaths and any safety problems. Although final blood pressures (systolic/diastolic) were significantly lower in the strict-treatment group compared with the mild-treatment group (135.9/74.8 vs. 145.6/78.1 mmHg; p<0.001), the incidence of the primary endpoint was similar in the two groups (86 patients in each group; p=0.99). Total deaths were 54 in the strict-treatment group vs. 42 in the mild-treatment group (p=0.22), and treatment was withdrawn because of adverse events in 36 patients in each group (p=0.99). An interaction between age and treatment for the primary endpoints (p=0.03) was seen. Complex clinical features associated with aging seem to have obscured the difference in effect between the two treatments. Further studies are needed to assess the optimal treatment strategy for hypertension in the elderly.


  1. 1

    Burt VL, Whelton P, Roccella EJ, et al: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 23: 305–313.

    Article  Google Scholar 

  2. 2

    Franklin SS, Larson MG, Khan SA, et al: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245–1249.

    CAS  Article  Google Scholar 

  3. 3

    Williams B, Lindholm LH, Sever P : Systolic pressure is all that matters. Lancet 2008; 371: 2219–2221.

    PubMed  Article  Google Scholar 

  4. 4

    Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003; 289: 2560–2572.

    CAS  Article  Google Scholar 

  5. 5

    European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  6. 6

    World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.

  7. 7

    Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl): S1–S105.

  8. 8

    Mancia G, Grassi G : Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20: 1461–1464.

    CAS  PubMed  Article  Google Scholar 

  9. 9

    Swales JD : Current status of hypertensive disease treatment: results from the Evaluation and Interventions for Systolic Blood Pressure Elevation: Regional and Global (EISBERG) project. J Hypertens 1999; 17 (Suppl 2): S15–S19.

    CAS  Article  Google Scholar 

  10. 10

    Ogihara T, Hiwada K, Morimoto S, et al: Guidelines for treatment of hypertension in the elderly—2002 revised version—. Hypertens Res 2003; 26: 1–36.

    PubMed  PubMed Central  Article  Google Scholar 

  11. 11

    Amery A, Birkenhäger W, Brixko R, et al: Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet 1986; 2: 589–592.

    CAS  PubMed  Article  Google Scholar 

  12. 12

    Staessen JA, Fagard R, Thijs L, et al: Subgroup and perprotocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 1998; 158: 1681–1691.

    CAS  PubMed  Article  Google Scholar 

  13. 13

    Hakala SM, Tilvis RS, Strandberg TE : Blood pressure and mortality in an older population. A 5-year follow-up of the Helsinki Ageing Study. Eur Heart J 1997; 18: 1019–1023.

    CAS  PubMed  Article  Google Scholar 

  14. 14

    Rothwell PM, Coull AJ, Silver LE, et al: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366: 1773–1783.

    CAS  PubMed  Article  Google Scholar 

  15. 15

    JATOS Study Group: The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res 2005; 28: 513–520.

    Article  Google Scholar 

  16. 16

    Masuda K, Takeguchi M, Arakawa C, et al: Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative. Arch Int Pharmacodyn Ther 1990; 304: 247–264.

    CAS  PubMed  Google Scholar 

  17. 17

    Yamada K, Ishii M, Mizuno Y, Nakajima M, Ohashi Y : Clinical evaluation of the antihypertensive effect of NZ-105 in subjects with essential hypertension: double-blind comparison between NZ-105 and nicardipine hydrochloride retard. Igaku No Ayumi 1992; 161: 275–292 (in Japanese).

    Google Scholar 

  18. 18

    Sokolow M, Lyon TP : The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37: 161–181.

    CAS  PubMed  Article  Google Scholar 

  19. 19

    Japan Diabetes Society: Guide for the Treatment of Diabetes Mellitus. Tokyo, Bunkodo, 1999 (in Japanese).

  20. 20

    Hata Y, Mabuchi H, Saito Y, et al: Report of the Japan Atherosclerosis Society (JAS) guideline for diagnosis and treatment of hyperlipidemia in Japanese adults. J Atheroscler Thromb 2002; 9: 1–27.

    Article  Google Scholar 

  21. 21

    Research Division, Nissan Chemical Industries, Ltd: A Summary of Post-marketing Surveillance Data for Efonidipine Hydrochloride 10 mg Tablets, 20 mg Tablets, and 40 mg Tablets. Tokyo, Nissan Chemical Industries, Ltd, 2000 ( in Japanese).

  22. 22

    Machin D, Cambell M, Fayers P, Pinol APY : Comparing two independent groups for binary, ordered categorical and continuous data. in Machin D, Cambell M, Fayers P, Pinol APY (eds): Sample Size Tables for Clinical Studies, 2nd ed. Oxford, Blackwell Scientific, 1997, pp 18–68.

    Google Scholar 

  23. 23

    Sahai H, Kurshid A : Statistics in Epidemiology: Methods Techniques and Application. Boca Raton, CRC Press, 1996, pp 1–321.

    Google Scholar 

  24. 24

    Langer RD, Criqui MH, Barrett-Connor EL, Klauber MR, Ganias TG : Blood pressure change and survival after age 75. Hypertension 1993; 22: 551–559.

    CAS  PubMed  Article  Google Scholar 

  25. 25

    Collins R, MacMahon S : Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272–298.

    CAS  PubMed  Article  Google Scholar 

  26. 26

    MacMahon S, Rodgers A : The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967–978.

    CAS  PubMed  Article  Google Scholar 

  27. 27

    Staessen JA, Gasowski J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872.

    CAS  PubMed  Article  Google Scholar 

  28. 28

    Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

  29. 29

    Asia Pacific Cohort Studies Collaboration: Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21; 707–716.

  30. 30

    Sairenchi T, Iso H, Irie F, et al: Age-specific relationship between blood pressure and the risk of total and cardiovascular mortality in Japanese men and women. Hypertens Res 2005; 28: 901–909.

    PubMed  PubMed Central  Article  Google Scholar 

  31. 31

    Murakami Y, Hozawa A, Okamura T, Ueshima H, Evidence for Cardiovascular Prevention from Observational Cohorts in Japan Research Group (EPOCH-JAPAN): Relation of blood pressure and all-cause mortality in 180,000 Japanese participants; pooled analysis of 13 chohort studies. Hypertension 2008; 51: 1483–1491.

    CAS  PubMed  Article  Google Scholar 

  32. 32

    Beckett NS, Peters RP, Fletcher AE, et al: Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–1898.

    CAS  PubMed  Article  Google Scholar 

  33. 33

    Borzecki AM, Glickman ME, Kader B, Berlowitz DR : The effect of age on hypertension control and management. Am J Hypertens 2006; 19: 520–527.

    PubMed  Article  Google Scholar 

  34. 34

    Szirmai LA, Arnold C, Farsang C : Improving control of hypertension by an integrated approach—results of the ‘Manage it well!’ programme. J Hypertens 2005; 23: 203–211.

    CAS  PubMed  Article  Google Scholar 

  35. 35

    European Working Party on High Blood Pressure in the Elderly (EWPHE): An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Arch Int Pharmacodyn 1985; 275: 300–334.

  36. 36

    MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–412.

  37. 37

    SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.

  38. 38

    Staessen JA, Fagard R, Thijs L, et al: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764.

    CAS  Article  Google Scholar 

  39. 39

    Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823–1829.

    CAS  Article  Google Scholar 

  40. 40

    Yoshinaga K, Une H : Contributions of mortality changes by age group and selected causes of death to the increase in Japanese life expectancy at birth from 1950 to 2000. Eur J Epidemiol 2005; 20: 49–57.

    PubMed  Article  Google Scholar 

Download references

Author information


Additional information

Masao Ishii, M.D., Yokohama Seamen's Insurance Hospital, 43–1, Kamadai-cho, Hodogaya-ku, Yokohama 240-8585, Japan. E-mail:

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jatos Study Group*. Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res 31, 2115–2127 (2008).

Download citation


  • essential hypertension
  • calcium antagonists
  • efonidipine hydrochloride
  • elderly patients

Further reading


Quick links